CN109078159A - It is a kind of for treating the cell nutritious element and production method of dry eyes - Google Patents
It is a kind of for treating the cell nutritious element and production method of dry eyes Download PDFInfo
- Publication number
- CN109078159A CN109078159A CN201811022164.9A CN201811022164A CN109078159A CN 109078159 A CN109078159 A CN 109078159A CN 201811022164 A CN201811022164 A CN 201811022164A CN 109078159 A CN109078159 A CN 109078159A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- substance
- mineral water
- dry eyes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
It is disclosed by the invention a kind of for treating the cell nutritious element of dry eyes, it is made of the substance that following weight matches: 55-65 parts of mineral water, 8-12 parts of chrysanthemum powder, 8-12 parts of wolfberry fruit powder, 8-12 parts of dendrobium nobile, 0.5-1.5 parts of ginger powder, 4-6 parts, 9 degree 3-5 parts of rice vinegar of cane suger;The mineral water is made of the substance that following weight matches: 8-12 parts of Lapis Micae Aureus, green 8-12 parts of chlorite schist, 8-12 parts of red halloysite, 35-45 parts of medical stone, 25-35 parts of stone needle.The cell nutritious element for being used to treat dry eyes in the present invention, rationally, ingredient is simple and easy to get for formula, at low cost, can prevent and improve xerophthalmia, and can alleviate visual fatigue, be beneficial to eye health in the promotion of eyesight.
Description
Technical field
The present invention relates to Dry eye treatment Chinese medicine preparation technical field more particularly to a kind of cell battalion for treating dry eyes
Support element and production method.
Background technique
Dry eyes, be due to tear amount or matter or fluid dynamics extremely caused by tear film is unstable and (or) ocular damage
Evil, so as to cause a kind of disease of eye malaise symptoms and visual disorder.
Dry eyes have become the common eye surface diseases of one kind for influencing people's quality of life, are the second largest eye disease of ophthalmology, in recent years
Come, disease incidence of the dry eyes in China is gradually increasing, and according to the literature, the disease incidence of dry eyes about exists in world wide at present
5%-35% etc., wherein women is higher than male, and old man is higher than young man, and Asian is higher than other ethnic groups, existing according to China
Epidemiological study show that disease incidence of the dry eyes in China is similar with other Asian countries, about 21% one 30%, thus may be used
See that dry eyes are tormenting always people, and everybody is also insufficient to the understanding of dry eyes, in treatment of some hospital ophthalmologies to dry eyes
It is lack of standardization, the treatment of dry eye disorders is affected very much in this way.
The rejuvenation trend of dry eyes is obvious in recent years, mainly due in the modern life, the work and amusement of young people with
TV, computer, smart phone etc. contact more and more, for a long time in face of fluorescent screen, excessively read, lack normal blink,
Lead to xerophthalmia, the injury to eyes is very it will be evident that can cause visual fatigue, and visual fatigue cardinal symptom there are eyes dry
It is puckery, itch, photophobia, shed tears, having that foreign body sensation, eyelid be heavy, blurred vision etc., visual fatigue early stage is reversible, by stopping
Breath, pays attention to the modes such as eye hygiene, can gradually alleviate, if but it is careless, can cause long-time or it is permanent
Inpairment of vision suffers from dry eye syndrome, or causes to induce early cataract and glaucoma, even may cause blindness.
Inventor has found that 10 people just have 9 people to have different degrees of a dry eyes and visual fatigue in the middle in outpatient service, especially in it is old
Year, crowd was more, and the treatment of ophthalmologic hospital at present generally uses artificial tears and anti-inflammatory drug to carry out improvement treatment, but curative effect is unknown
It is aobvious, and be all the liquid medicine using import, expensive, other instruments treatment technology does not obtain national authority report temporarily and faces
Bed is promoted.
Summary of the invention
In place of avoiding the deficiencies in the prior art, a kind of cell battalion for treating dry eyes is provided
Element and production method are supported, to effectively solve the shortcomings of the prior art.
To achieve the above object, the technical scheme adopted by the invention is as follows: it is a kind of for treating the cell nutritious element of dry eyes,
It is made of the substance of following weight proportion: 55-65 parts of mineral water, 8-12 parts of chrysanthemum powder, 8-12 parts of wolfberry fruit powder, dendrobium nobile
8-12 parts, 0.5-1.5 parts of ginger powder, 4-6 parts, 9 degree 3-5 parts of rice vinegar of cane suger;
The mineral water is made of the substance that following weight matches: 8-12 parts of Lapis Micae Aureus, green 8-12 parts of chlorite schist, red stone
8-12 parts of rouge, 35-45 parts of medical stone, 25-35 parts of stone needle.
Further, it is made of the substance that following weight matches: 58-62 parts of mineral water, 9-11 parts of chrysanthemum powder, Chinese holly
9-11 parts of Qi powder, 9-11 parts of dendrobium nobile, 0.8-1.2 parts of ginger powder, 4.5-5.5 parts, 9 degree 3.5-4.5 parts of rice vinegar of cane suger;
The mineral water is made of the substance that following weight matches: 9-11 parts of Lapis Micae Aureus, green 9-11 parts of chlorite schist, red stone
9-11 parts of rouge, 38-42 parts of medical stone, 28-32 parts of stone needle.
Further, it is made of the substance that following weight matches: 60 parts of mineral water, 10 parts of chrysanthemum powder, wolfberry fruit powder 10
Part, 10 parts of dendrobium nobile, 1 part of ginger powder, 5 parts, 9 degree 4 parts of rice vinegar of cane suger;
The mineral water is made of the substance that following weight matches: 10 parts of Lapis Micae Aureus, green 10 parts of chlorite schist, red halloysite 10
Part, 40 parts of medical stone, 30 parts of stone needle.
A kind of above-mentioned production method for treating the cell nutritious element of dry eyes, includes the following steps:
Step 1: the Lapis Micae Aureus of certain weight ratio, green chlorite schist, red halloysite, medical stone, stone needle are mixed and wears into 1mm powder
Then pure water is added in end, boil, and boil condition is kept for 25-35 minutes later, after being cooled to room temperature, filters, filtrate is
Mineral water;
Step 2: mineral water, chrysanthemum powder, wolfberry fruit powder, dendrobium nobile, ginger powder, cane suger, 9 degree of rice vinegar part solution are mixed
It closes, is added in reaction kettle container and is uniformly mixed, filtering, filtrate is in the cell nutritious element for the treatment of dry eyes.
Further, it in the step 1 and step 2, is filtered using the sieve of 400-600 mesh.
Further, before the filtering technique of the step 1 and step 2, high-temperature disinfection treatment is carried out.
Above-mentioned technical proposal of the invention has the advantages that the cell battalion for treating dry eyes in the present invention
Element is supported, rationally, ingredient is simple and easy to get for formula, and it is at low cost, it can prevent and improve xerophthalmia, and visual fatigue can be alleviated, have
Beneficial to eye health in the promotion of eyesight;Basal nutrient substance is provided for eye cell, main nutrient composition is that body is rare
Multielement mineral and amino acid are injected directly into intraocular and eye circumference and enclose, and tiny molecule is quickly by ocular absorption, to be converted into
The power of eyes repairs meibomian gland dysfunction;Tear film stability can be improved;The apoptosis of energy protective epithelium cell;Ocular can be improved
Cell viability;Can improve eye is dry and astringent, itch and visual fatigue act on;The basal nutrient substance of eyes can be provided;Safe and non-toxic secondary work
With;Production procedure and product cost are controllable;Avoid at present treatment xerophthalmia used in hormone medicine side effect with
And artificial tears, lacrimal secretion excitants etc. are unable to improve in xerophthalmia the cause of disease the problem of, there is good practical value.
Specific embodiment
Embodiments of the present invention are described in further detail below with reference to embodiment.Following embodiment is for illustrating
The present invention, but cannot be used to limit the scope of the invention.
In the description of the present invention, unless otherwise indicated, the meaning of " plurality " is two or more.In the present invention
Description in, it should be noted that unless otherwise clearly defined and limited, term " connected ", " connection " should do broad sense reason
Solution, for example, it may be being fixedly connected, may be a detachable connection, or be integrally connected;It can be mechanical connection, it can also be with
It is electrical connection;It can be directly connected, it can also be indirectly connected through an intermediary.For those of ordinary skill in the art
For, the concrete meaning of above-mentioned term in the present invention can be understood with concrete condition.
The preparation of the present embodiment spray:
Step 1: taking 100 grams of Lapis Micae Aureus, green 100 grams of chlorite schist, 100 grams of red halloysite, 400 grams of medical stone and 300 grams of stone needle,
Wear into 1mm powder after mixing, pure water be then added, boil, later boil condition keep 30 minutes, then successively carry out through
High-temperature sterilization, clarification, filtering, filtrate are mineral water, and in the present embodiment, clarification and filtering pass through the sieve of 500 mesh
Net realizes that high-temperature sterilization is pharmaceutically conventional disinfection way;
Step 2: taking 600 grams of obtained mineral water in step 1, takes 100 grams of chrysanthemum powder, 100 grams of wolfberry fruit powder, stone
100 grams of dry measure used in former times, 10 grams of ginger powder, 50 grams, 9 degree 40 grams of rice vinegar of cane suger, above-mentioned substance is mixed, and is added to reaction kettle appearance
It is uniformly mixed in device, then successively through high-temperature sterilization, filtering, filtrate is the cell nutritious element for being used to treat dry eyes, by cell
Spray is made in nutrient, in the present embodiment, is filtered through the sieve of 500 mesh to realize, high-temperature sterilization is pharmaceutically conventional
Disinfection way.
In the present embodiment, it is necessary first to formulate the diagnostic criteria of an xerophthalmia:
Following diagnostic criteria is formulated according to dry eyes clinic diagnosis Consensus of experts (2013): 1, having dry sensation, foreign matter
One of subjective symptoms such as sense, burn feeling, feeling of fatigue, sense of discomfort, eyesight fluctuation and BUT < 5s or Schirmer I test (no table
Facial anesthesia) the diagnosable dry eyes of < 5mm/5min;2, there are dry sensation, foreign body sensation, burn feeling, feeling of fatigue, sense of discomfort, eyesight fluctuation
Etc. one of subjective symptoms and 5s < BUT (calling " breakup time of tear film " in the following text) < 10s or 5mm/5min < Schirmer I test
When (calling " Schimer's test " in the following text) (no surface anesthesia) < 10mm/5min, while there is the angle conjunctiva fluorescent staining positive that can examine
Trunk snap eye.
Inventor country operation ophthalmology middle rank eye doctor carried out clinical observation to 300 patients by 3 years, uses
Preceding requirement all fills in treatment registration form, and to record entire diagnosis process, the training and learning exercised before using of going forward side by side guarantees patient
Medication is correct.
Patient's selection standard:
1, meet above-mentioned diagnostic criteria, the age 20-70 years old, be ready to treat using spray;2, without general immunity disease;
3, without lid abnormity, no glaucoma medical history, no gestational patients.
Patients with dry eye 100 for meeting above-mentioned standard are randomly selected in above-mentioned 300 patients, wherein male 43, female
57, patient age 23-70 years old, 35.6 years old average, disease time is 1-8 weeks.
It is treated using the spray prepared in the present embodiment, morning, noon, the total treatment four of afternoon, one day at night
It is secondary, treatment when cell nutritious element is sprayed it is pleasing to the eye, 0.2 milliliter every time, continuous treatment one month.
Effective evaluation standard:
1, remarkable result: symptom disappears, and angle conjunctiva fluorescent staining is negative, and Schimer's test is greater than 10mm/5min,
Breakup time of tear film is greater than 10s;
2, effectively: symptom mitigates, and angle conjunctiva fluorescent staining is reduced, Schimer's test 5-10mm/5min, and tear film is broken
Split time 5-10s;
3, invalid: symptom improvement is unobvious, and for angle conjunctiva fluorescent staining in rare dotted coloring, Schimer's test is small
In 5mm/5min, breakup time of tear film is less than 5s.
As a result:
By treatment, the symptom of 100 patients disappears, and angle conjunctiva fluorescent staining is feminine gender, Schimer's test
As a result it is all larger than 10mm/5min, breakup time of tear film is all larger than 10s, therefore all meets effective standard.
Adverse reaction:
Follow-up observation is carried out for 100 patients over the course for the treatment of, does not find apparent adverse reaction.
Several typical cases:
Mr. Wang, male, 25 years old, because feeling that ophthalmic uncomfortable carrys out hospital admission inquiry, by checking, eyes had xerophthalmia positive
History of venereal disease and subjective symptoms, Schimer's test 2.5mm/5min, breakup time of tear film 2s, the dyeing of corneal fluorescein sodium
Visible corneal epithelium is dispersed in dotted coloring afterwards, and with dry nasal cavity dryness, the symptom of dry skin is diagnosed as xerophthalmia, through inquiring,
Sick time is 1 week, is treated using the spray prepared in embodiment, 4 times a day, 0.2 milliliter every time, continuously treats one
A month;By treatment, the ophthalmic uncomfortable sense of Mr. Wang disappears, and consciously without any uncomfortable, angle conjunctiva fluorescent staining is negative,
Schimer's test is 13mm/5min, breakup time of tear film 15s;Meet effective standard through treatment.
Sun, female, 32 years old, because ophthalmic uncomfortable carrys out hospital therapy, on inspection, eyes have xerophthalmia positive history and
Subjective symptoms, Schimer's test 3mm/5min, breakup time of tear film 3s, visible cornea after the dyeing of corneal fluorescein sodium
Epithelium is dispersed in dotted coloring, is diagnosed as xerophthalmia, through inquiring, sick time be 3 weeks, using the spray prepared in embodiment 1 into
Row treatment, 4 times a day, 0.2 milliliter every time, continuous treatment one month;By treatment, the ophthalmic uncomfortable sense of Sun disappears, angle
Conjunctiva fluorescent staining is negative, Schimer's test 15mm/5min, breakup time of tear film 16s;Meet through treatment effective
Standard.
Poplar, female, 45 years old, because ophthalmic uncomfortable carrys out hospital therapy, on inspection, eyes had xerophthalmia positive history and oneself
Feel symptom, Schimer's test 4mm/5min, breakup time of tear film 3s, after the dyeing of corneal fluorescein sodium on visible cornea
Skin is dispersed in dotted coloring, is diagnosed as xerophthalmia, and through inquiring, sick time is 2 weeks, is carried out using the spray prepared in embodiment
Treatment, 4 times a day, 0.2 milliliter every time, continuous treatment one month;By treatment, the ophthalmic uncomfortable sense of poplar disappears, angle knot
Film fluorescent staining is negative, Schimer's test 14mm/5min, breakup time of tear film 18s;Meet through treatment effective
Standard.
Liu, male, 61 years old, because ophthalmic uncomfortable carrys out hospital therapy, on inspection, eyes had xerophthalmia positive history and oneself
Feel symptom, Schimer's test 4.3mm/5min, breakup time of tear film 4s, visible cornea after the dyeing of corneal fluorescein sodium
Epithelium is dispersed in dotted coloring, is diagnosed as xerophthalmia, through inquiring, sick time be 4 weeks, using the spray prepared in embodiment into
Row treatment, 4 times a day, 0.2 milliliter every time, continuous treatment one month;By treatment, the ophthalmic uncomfortable sense of poplar disappears, angle
Conjunctiva fluorescent staining is negative, Schimer's test 16mm/5min, breakup time of tear film 17s;Meet through treatment effective
Standard.
In addition, the present invention also has effects that improve visual fatigue.
It is randomly selected in above-mentioned 300 patients with visual fatigue patient 50, wherein male 26, female 24, Huan Zhenian
Age 20-63 years old, 33.7 years old average, according to medication discovery later is required, after 3 days, the alleviation of visual fatigue starts to take effect,
In 7-12 days, eyes have been relieved fatigue, and after 12 days, asthenopia disappears, and effect is obvious.
The embodiment of the present invention is given for the purpose of illustration and description, and is not that exhaustively or incite somebody to action this
Invention is limited to disclosed form.Many modifications and variations are obvious for the ordinary skill in the art.
Selection and description embodiment are and to make the ordinary skill of this field to more preferably illustrate the principle of the present invention and practical application
Personnel it will be appreciated that the present invention to designing various embodiments suitable for specific applications with various modifications.
Claims (6)
1. a kind of for treating the cell nutritious element of dry eyes, which is characterized in that it is made of the substance that following weight matches: mine
55-65 parts of substance water, 8-12 parts of chrysanthemum powder, 8-12 parts of wolfberry fruit powder, 8-12 parts of dendrobium nobile, 0.5-1.5 parts of ginger powder, cane suger 4-6
Part, 9 degree 3-5 parts of rice vinegar;
The mineral water is made of the substance that following weight matches: 8-12 parts of Lapis Micae Aureus, green 8-12 parts of chlorite schist, red halloysite 8-12
Part, 35-45 parts of medical stone, 25-35 parts of stone needle.
2. according to claim 1 a kind of for treating the cell nutritious element of dry eyes, it is characterised in that: it is by following heavy
The substance of amount proportion is made: 58-62 parts of mineral water, 9-11 parts of chrysanthemum powder, 9-11 parts of wolfberry fruit powder, 9-11 parts of dendrobium nobile, ginger powder
0.8-1.2 parts, 4.5-5.5 parts, 9 degree 3.5-4.5 parts of rice vinegar of cane suger;
The mineral water is made of the substance that following weight matches: 9-11 parts of Lapis Micae Aureus, green 9-11 parts of chlorite schist, red halloysite 9-11
Part, 38-42 parts of medical stone, 28-32 parts of stone needle.
3. according to claim 1 a kind of for treating the cell nutritious element of dry eyes, it is characterised in that: it is by following heavy
The substance of amount proportion is made: 60 parts of mineral water, 10 parts of chrysanthemum powder, 10 parts of wolfberry fruit powder, 10 parts of dendrobium nobile, 1 part of ginger powder, cane suger
5 parts, 9 degree 4 parts of rice vinegar;
The mineral water is made of the substance that following weight matches: 10 parts of Lapis Micae Aureus, green 10 parts of chlorite schist, 10 parts of red halloysite, wheat
40 parts of meal stone, 30 parts of stone needle.
4. a kind of production method as claimed in any one of claims 1-3 for treating the cell nutritious element of dry eyes, special
Sign is, includes the following steps:
Step 1: the Lapis Micae Aureus of certain weight ratio, green chlorite schist, red halloysite, medical stone, stone needle are mixed and wears into 1mm powder, then
Pure water is added, boils, boil condition is kept for 25-35 minutes later, and after being cooled to room temperature, filtering, filtrate is mineral water;
Step 2: mineral water, chrysanthemum powder, wolfberry fruit powder, dendrobium nobile, ginger powder, cane suger, 9 degree of rice vinegar part solution are mixed, are added
It is uniformly mixed into reaction kettle container, filtering, filtrate is in the cell nutritious element for the treatment of dry eyes.
5. production method according to claim 4, which is characterized in that in the step 1 and step 2, using 400-
The sieve of 600 mesh is filtered.
6. production method according to claim 4, which is characterized in that the filtering technique of the step 1 and step 2 it
Before, to carry out high-temperature disinfection treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811022164.9A CN109078159A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for treating the cell nutritious element and production method of dry eyes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811022164.9A CN109078159A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for treating the cell nutritious element and production method of dry eyes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109078159A true CN109078159A (en) | 2018-12-25 |
Family
ID=64840727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811022164.9A Pending CN109078159A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for treating the cell nutritious element and production method of dry eyes |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109078159A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102824547A (en) * | 2012-09-20 | 2012-12-19 | 于耀光 | Traditional Chinese medicine ultrasonic atomization agent for treating xerophthalmia and preparation method thereof |
CN103356697A (en) * | 2012-03-28 | 2013-10-23 | 闫斌 | Stem cell preparation and oral fluid prepared therefrom |
CN107998148A (en) * | 2017-10-25 | 2018-05-08 | 闫荣平 | A kind of stem cell factor powder, its preparation method and its oral liquid of preparation |
-
2018
- 2018-09-04 CN CN201811022164.9A patent/CN109078159A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103356697A (en) * | 2012-03-28 | 2013-10-23 | 闫斌 | Stem cell preparation and oral fluid prepared therefrom |
CN102824547A (en) * | 2012-09-20 | 2012-12-19 | 于耀光 | Traditional Chinese medicine ultrasonic atomization agent for treating xerophthalmia and preparation method thereof |
CN107998148A (en) * | 2017-10-25 | 2018-05-08 | 闫荣平 | A kind of stem cell factor powder, its preparation method and its oral liquid of preparation |
Non-Patent Citations (4)
Title |
---|
吴林玲: "《《黄帝内经》和《本草纲目》中的女人养颜经》", 30 June 2014, 天津科学技术出版社 * |
屠亦文: "《长寿食单 一生的长寿计划》", 30 April 2011, 团结出版社 * |
王耀堂: "《大国医 第二季 第二届国宝级"国医大师"的祛病长寿秘诀》", 31 December 2016, 科学技术文献出版社 * |
赵青: "《小方子治大病》", 31 May 2014, 江西科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
CN109010761A (en) | A kind of eye externally applied drug and preparation method thereof alleviated visual fatigue and improve eyesight | |
Kaback et al. | Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5% | |
CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
CN103720857A (en) | Traditional Chinese medicinal preparation for treating fundus macular oedema lesion | |
CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
CN113425789B (en) | Traditional Chinese medicine composition for treating xerophthalmia accompanied with sleep disorder | |
CN109394987A (en) | The composition and preparation method thereof with treatment eye disease containing dimethyl fumarate | |
CN109078159A (en) | It is a kind of for treating the cell nutritious element and production method of dry eyes | |
CN110448618A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating eyesight | |
Gay et al. | Topical sympatholytic therapy for pathologic lid retraction | |
CN113786452A (en) | Traditional Chinese medicine composition for treating allergic conjunctivitis and/or allergic rhinitis | |
CN112107623B (en) | Traditional Chinese medicine composition for improving meibomian gland function | |
Sithole | The ocular complications of an envenomous snakebite | |
Vachhani et al. | Chakshushya Basti and Adjuvant Ayurvedic Remedies in the Management of Keratoconus–A Case Report | |
CN103877430B (en) | A kind of medicine and preparation method for the treatment of degeneration of macula | |
AU2020352751B2 (en) | Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters | |
CN1073600A (en) | The preparation method of the Chinese medicine preparation of treatment pseudomyopia | |
Chmielarz-Czarnocińska et al. | Ophthalmic applications of cyclopentolate | |
CN105920060A (en) | Medicine composition containing iodized lecithin and preparation method thereof | |
Narayanan et al. | Management of Proliferative Diabetic Retinopathy and its Associated Conditions using Ayurvedic Therapies: A Case Series | |
Pramanandari | Blunt Ocular Trauma Complicated by Hyphema | |
CN104873668A (en) | Traditional Chinese medicine composition for treating optic atrophy | |
Sharma et al. | A CASE STUDY OF CENTRAL SEROUS CHORIORETINOPATHY IN A PATIENT TREATED WITH AYURVEDIC MANAGEMENT | |
CN104887801A (en) | Traditional Chinese medicine preparation for treating cataract extracapsular postoperative inflammatory response and nursing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |